Steven Cohen Celldex Therapeutics, Inc. Transaction History

Point72 Asset Management, L.P.

$39.3 Billion
Q1 2024

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 1,283,797 shares of CLDX stock, worth $42.8 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares

1,283,797

Previous 2,756,122 53.42%

Holding current value

$42.8 Million

Previous $109 Million 50.71%

% of portfolio

0.14%

Previous 0.28%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$35.22 - $51.88 $51.9 Million - $76.4 Million	-1,472,325 Reduced 53.42%	1,283,797 $53.9 Million
Q4 2023 Feb 14, 2024	BUY	$22.61 - $40.65 $32 Million - $57.5 Million	1,413,722 Added 105.31%	2,756,122 $109 Million
Q3 2023 Nov 14, 2023	BUY	$25.45 - $37.46 $4.01 Million - $5.9 Million	157,600 Added 13.3%	1,342,400 $36.9 Million
Q2 2023 Aug 14, 2023	BUY	$30.29 - $38.28 $28.9 Million - $36.6 Million	955,297 Added 416.25%	1,184,800 $40.2 Million
Q1 2023 May 15, 2023	SELL	$34.78 - $47.43 $9.61 Million - $13.1 Million	-276,297 Reduced 54.63%	229,503 $8.26 Million

Q4 2022 Feb 14, 2023	BUY	$27.78 - $45.38 $10.3 Million - $16.8 Million	370,800 Added 274.67%	505,800 $22.5 Million
Q3 2022 Nov 14, 2022	BUY	$22.7 - $37.57 $3.06 Million - $5.07 Million	135,000 New	135,000 $3.8 Million
Q2 2021 Aug 16, 2021	SELL	$20.71 - $35.37 $954,731 - $1.63 Million	-46,100 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$16.19 - $29.91 $746,359 - $1.38 Million	46,100 New	46,100 $950,000

Others Institutions Holding CLDX

# of Institutions

207

Shares Held

61.2M

Call Options Held

291K

Put Options Held

246K

View Full List

About Celldex Therapeutics, Inc.

Ticker CLDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,772,400
Market Cap $1.56B
Description
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...

More about CLDX

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account